Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in symptomatic patients, supporting diagnosis, according ...
SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting ...
The laboratory-developed test, named AD-Detect™ Abeta 42/40 and p-tau217 Evaluation, combines results of blood levels of amyloid beta (AB) 42/40 determined by the company's proprietary tandem mass ...
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback